secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002822
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus
-------------------------------------------------------------------------------

- Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).
- ELEVIDYS net product revenue of $131.3M in Q4 and $200.4M for FY2023, significantly exceeding consensus.
- RNA-based PMO net revenue of $234.3M in Q4 and $945.0M for FY2023.
- Preliminary cash, equivalents, restricted cash and investments of ~$1.7B as of Dec 31, 2023.
- Company to report final Q4/FY2023 results in late February 2024; results subject to adjustment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/0000950170-24-002822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017024002822/srpt-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer